In addition, the present findings indicate that targeting HIF1α or its downstream effectors may represent alternative clinical targets in breast cancer, and further highlight the possibility that these approaches may also be effective on cells at very initial stages of breast cancer formation. This evidence concerns the gene HIF1A and breast cancer.